Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice

Results of a multicenter study

Lee Schwartzberg, Edward J. Stepanski, Mark S. Walker, Susan Mathias, Arthur C. Houts, Barry V. Fortner

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Goals of work: Targeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However, there is a risk of developing infusion reactions (IRs) with MoAbs. This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux®) and rituximab (Rituxan®). Patients and methods: A prospective multicenter study involving time and motion and activity sampling methods was conducted among patients with cancer receiving their first outpatient infusion of cetuximab or rituximab. Patients were observed from initiation of MoAb infusion to the end of the clinic visit. IRs were classified as absent, mild/moderate, and severe/life threatening. Staff time and costs were estimated for preparation and administration of MoAb, other chemotherapy agents, and for management of IRs. Resource costs were compared across IR groups within each MoAb. Main results: Among 161 patients enrolled, 32% of 71 patients on cetuximab and 39% of 90 patients on rituximab experienced IRs. Treatment of patients who experienced IRs required more staff time (31-80% more time) and resulted in higher human resource costs (increase of 17-65 US dollars) than patients who did not experience IRs. Conclusions: IRs following cetuximab and rituximab administration are common and are associated with measurably increased costs of care. The frequency of IRs suggests the importance of identifying clinical guidelines for intervention and management.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalSupportive Care in Cancer
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Caregivers
Multicenter Studies
Monoclonal Antibodies
Costs and Cost Analysis
Ambulatory Care
Neoplasms
Outpatients
Cetuximab
Rituximab
Prospective Studies
Guidelines
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice : Results of a multicenter study. / Schwartzberg, Lee; Stepanski, Edward J.; Walker, Mark S.; Mathias, Susan; Houts, Arthur C.; Fortner, Barry V.

In: Supportive Care in Cancer, Vol. 17, No. 1, 01.01.2009, p. 91-98.

Research output: Contribution to journalArticle

Schwartzberg, Lee ; Stepanski, Edward J. ; Walker, Mark S. ; Mathias, Susan ; Houts, Arthur C. ; Fortner, Barry V. / Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice : Results of a multicenter study. In: Supportive Care in Cancer. 2009 ; Vol. 17, No. 1. pp. 91-98.
@article{2763cc8dc14f43ec8cd586e2222549e3,
title = "Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: Results of a multicenter study",
abstract = "Goals of work: Targeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However, there is a risk of developing infusion reactions (IRs) with MoAbs. This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux{\circledR}) and rituximab (Rituxan{\circledR}). Patients and methods: A prospective multicenter study involving time and motion and activity sampling methods was conducted among patients with cancer receiving their first outpatient infusion of cetuximab or rituximab. Patients were observed from initiation of MoAb infusion to the end of the clinic visit. IRs were classified as absent, mild/moderate, and severe/life threatening. Staff time and costs were estimated for preparation and administration of MoAb, other chemotherapy agents, and for management of IRs. Resource costs were compared across IR groups within each MoAb. Main results: Among 161 patients enrolled, 32{\%} of 71 patients on cetuximab and 39{\%} of 90 patients on rituximab experienced IRs. Treatment of patients who experienced IRs required more staff time (31-80{\%} more time) and resulted in higher human resource costs (increase of 17-65 US dollars) than patients who did not experience IRs. Conclusions: IRs following cetuximab and rituximab administration are common and are associated with measurably increased costs of care. The frequency of IRs suggests the importance of identifying clinical guidelines for intervention and management.",
author = "Lee Schwartzberg and Stepanski, {Edward J.} and Walker, {Mark S.} and Susan Mathias and Houts, {Arthur C.} and Fortner, {Barry V.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s00520-008-0474-5",
language = "English (US)",
volume = "17",
pages = "91--98",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice

T2 - Results of a multicenter study

AU - Schwartzberg, Lee

AU - Stepanski, Edward J.

AU - Walker, Mark S.

AU - Mathias, Susan

AU - Houts, Arthur C.

AU - Fortner, Barry V.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Goals of work: Targeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However, there is a risk of developing infusion reactions (IRs) with MoAbs. This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux®) and rituximab (Rituxan®). Patients and methods: A prospective multicenter study involving time and motion and activity sampling methods was conducted among patients with cancer receiving their first outpatient infusion of cetuximab or rituximab. Patients were observed from initiation of MoAb infusion to the end of the clinic visit. IRs were classified as absent, mild/moderate, and severe/life threatening. Staff time and costs were estimated for preparation and administration of MoAb, other chemotherapy agents, and for management of IRs. Resource costs were compared across IR groups within each MoAb. Main results: Among 161 patients enrolled, 32% of 71 patients on cetuximab and 39% of 90 patients on rituximab experienced IRs. Treatment of patients who experienced IRs required more staff time (31-80% more time) and resulted in higher human resource costs (increase of 17-65 US dollars) than patients who did not experience IRs. Conclusions: IRs following cetuximab and rituximab administration are common and are associated with measurably increased costs of care. The frequency of IRs suggests the importance of identifying clinical guidelines for intervention and management.

AB - Goals of work: Targeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However, there is a risk of developing infusion reactions (IRs) with MoAbs. This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux®) and rituximab (Rituxan®). Patients and methods: A prospective multicenter study involving time and motion and activity sampling methods was conducted among patients with cancer receiving their first outpatient infusion of cetuximab or rituximab. Patients were observed from initiation of MoAb infusion to the end of the clinic visit. IRs were classified as absent, mild/moderate, and severe/life threatening. Staff time and costs were estimated for preparation and administration of MoAb, other chemotherapy agents, and for management of IRs. Resource costs were compared across IR groups within each MoAb. Main results: Among 161 patients enrolled, 32% of 71 patients on cetuximab and 39% of 90 patients on rituximab experienced IRs. Treatment of patients who experienced IRs required more staff time (31-80% more time) and resulted in higher human resource costs (increase of 17-65 US dollars) than patients who did not experience IRs. Conclusions: IRs following cetuximab and rituximab administration are common and are associated with measurably increased costs of care. The frequency of IRs suggests the importance of identifying clinical guidelines for intervention and management.

UR - http://www.scopus.com/inward/record.url?scp=57849108928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849108928&partnerID=8YFLogxK

U2 - 10.1007/s00520-008-0474-5

DO - 10.1007/s00520-008-0474-5

M3 - Article

VL - 17

SP - 91

EP - 98

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -